FAQ

CLAYRAS is located in Surat, Gujarat, India. The company has been operating in pharmaceutical API export coordination and supply support since 2019, with structured B2B communication for international pharmaceutical API procurement.

CLAYRAS differentiates itself through a compliance-focused, documentation-aware B2B approach. Every inquiry is reviewed around API identity, CAS number, grade, destination market, documentation expectations, and commercial feasibility. CLAYRAS focuses on structured requirement review, principal-to-principal communication, product-specific export coordination, and organized follow-up.

CLAYRAS works with B2B pharmaceutical buyers including pharmaceutical manufacturers, API importers, distributors, wholesalers, trading companies, regulatory affairs teams, institutional buyers, research organizations, and procurement departments. CLAYRAS is designed for business-to-business API discussions and is not a consumer-facing supplier.

CLAYRAS maintains a reference portfolio of 88+ pharmaceutical APIs across 10 therapeutic categories including Human API Range, Cortico-Steroids, Hormonal APIs, Cardiovascular APIs, Anti-Diabetic APIs, Anti-Infective APIs, CNS APIs, Oncology APIs, Pain Management APIs, and Gastro APIs. Final availability, grade, documentation, pricing, MOQ, and export feasibility are reviewed product-wise and source-wise.

CLAYRAS supports export inquiry coordination across Human API Range, Cortico-Steroids, Hormonal APIs, Cardiovascular APIs, Anti-Diabetic APIs, Anti-Infective APIs, CNS APIs, Oncology APIs, Pain Management APIs, and Gastro APIs. Buyers should share the API name, CAS number, grade, quantity, destination country, and required documents for product-wise review.

Yes. CLAYRAS supports export inquiry coordination for Cortico-Steroid APIs such as Beclomethasone Dipropionate, Betamethasone derivatives, Budesonide, Clobetasol Propionate, Dexamethasone, Fluticasone Propionate, Hydrocortisone, Methylprednisolone, Mometasone Furoate, Prednisolone, and Triamcinolone Acetonide. Each product is reviewed for grade, documentation, CAS number, quantity, and destination-market feasibility.

Yes. CLAYRAS supports export inquiry coordination for selected Hormonal APIs including Progesterone, Norethisterone, Hydroxyprogesterone Caproate, Testosterone derivatives, Estradiol, Levonorgestrel, Medroxyprogesterone Acetate, Ethinyl Estradiol, and Nandrolone Decanoate. Hormonal API inquiries require detailed documentation, end-use declaration, and destination-market review.

CLAYRAS Human API Range products are typically available in IP, BP, and USP grades, with some products also available in IHS grade. Cortico-Steroid and Hormonal API grades are reviewed product-wise. Buyers should specify the required pharmacopoeial grade with the API name, CAS number, and destination country.

Yes. CLAYRAS reviews Oncology and CNS API export requirements on a product-by-product basis. These categories are handled with attention to product identity, CAS number, grade, destination country, documentation requirements, and commercial feasibility.

MOQ, pricing, and lead time are determined based on API product and source, required grade, packaging type, required documentation, destination market, logistics mode, incoterms, and commercial terms. Complete requirement details are needed for an efficient review.

Payment terms, proforma invoice, commercial conditions, shipment timelines, and other commercial arrangements are generally discussed after product-level requirement review, source alignment, documentation expectations, and quantity finalization.

No. CLAYRAS does not guarantee availability, pricing, MOQ, lead time, sample availability, document supply, or export feasibility until formal requirement review is completed. Initial communication should not be treated as a binding commitment.

CLAYRAS can discuss incoterms for pharmaceutical API exports from India including FOB, CIF, EXW, and others based on buyer and destination requirements. The applicable incoterm is determined during commercial coordination.

CLAYRAS Human API Range products carry WHO-GMP context from source manufacturers. API grades may include IP, BP, USP, and IHS. Cortico-Steroid APIs carry GMP/GLP/DMF document context. Compliance is reviewed product-wise and source-wise based on destination-market requirements.

CLAYRAS supports institutional buyers, government procurement teams, and tender-oriented buyers requiring structured product documentation, WHO-GMP references, and export communication. Final eligibility depends on destination-market requirements, product documentation, and source verification.

CLAYRAS structures every inquiry around API name, CAS number, grade, quantity, destination country, documentation expectations, buyer type, and purchase timeline. This reduces miscommunication and improves review accuracy before commercial commitments.

CLAYRAS can be contacted by email at export@clayras.com, phone/WhatsApp at +91 9913905000, and through the website contact form at clayras.com/contact. Buyers should mention API category, API name, CAS number, grade, quantity, destination country, and required documents in the first message.

For an efficient response, include the full API name and CAS number, required grade, target quantity, purchase frequency, destination country, expected shipment timeline, buyer type, required documents, company name, and contact details.

CLAYRAS supports API export communication for buyers across multiple international markets including Asia, the Middle East, Africa, Europe, and other regions. Inquiries are reviewed based on destination-country regulatory context and import feasibility.

Depending on the API, source, destination market, and commercial stage, documents such as COA, MSDS/SDS, TDS, product specification, DMF, CEP, Written Confirmation, GMP certificate, GLP reference, packaging details, storage conditions, and other product-specific documents may be discussed. Document availability depends on product, source manufacturer, batch, destination market, quantity, and commercial terms.

A COA is a batch-specific analytical document for a pharmaceutical API. It typically includes test parameters, specification limits, results, and batch identification details. In API sourcing, it is commonly requested for quality verification. The COA format, parameters, validity, and availability depend on product, source manufacturer, batch, and transaction stage.

MSDS or SDS is a regulatory safety document that provides hazard, handling, storage, transportation, and emergency response information for a pharmaceutical chemical or API. It is important for safe logistics planning, import compliance, and regulatory submissions.

A DMF is a regulatory document submitted to health authorities containing confidential information about facilities, processes, and specifications used in API manufacturing. DMF availability is reviewed product-wise and source-wise. Buyers should mention the required authority or market context during inquiry.

A CEP is issued by EDQM and confirms that an API meets European Pharmacopoeia quality standards. CEP is commonly required for API exports to EU member states and certain regulated markets. CLAYRAS reviews CEP availability product-wise and source-wise.

No. Document availability is not guaranteed before formal review. COA, MSDS, TDS, DMF, CEP, GMP, GLP, Written Confirmation, and other documents depend on the API, source manufacturer, batch, destination market, buyer quantity, commercial stage, and applicable terms. Buyers should specify required documents at the inquiry stage.

WHO-GMP refers to Good Manufacturing Practice certification aligned with World Health Organization standards. WHO-GMP context is commonly required by regulatory authorities in Asia, Africa, the Middle East, and other regulated markets for API import approvals and tender eligibility.

Yes. CLAYRAS supports API export communication, documentation coordination, packaging planning, shipment discussion, and buyer follow-up for international pharmaceutical API requirements from India. CLAYRAS works with buyers across Asia, the Middle East, Africa, Europe, and other global markets.

The destination country determines import documentation requirements, regulatory approvals, pharmacopoeial grade expectations, import licensing, customs procedures, shipment restrictions, and commercial feasibility. Buyers should mention the destination country early in the inquiry.

Yes. Shipment mode, packaging specifications, storage conditions, incoterms such as FOB, CIF, EXW, and related logistics expectations can be discussed during commercial coordination. Final arrangements depend on the API, quantity, destination country, source context, and buyer requirements.

Principal-to-principal trade refers to a direct B2B trade relationship with clear accountability on both sides. CLAYRAS supports structured principal-to-principal communication for documentation flow, requirement accountability, and export follow-up.

Hormonal APIs and certain regulated pharmaceutical substances require special handling. CLAYRAS reviews such requirements with attention to destination-country classification, end-use documentation, export license or NOC requirements, and source-wise documentation. Buyers should share complete end-use and destination context.

To submit an inquiry, share the API name and CAS number, required grade or pharmacopoeial specification, target quantity, destination country, shipment timeline, required documents, buyer type, company details, and contact information. Inquiries can be submitted through the website, email, or WhatsApp/phone.

Yes. CLAYRAS supports bulk API requirement review, repeat procurement planning, and long-term pharmaceutical API supply communication for B2B buyers. Final feasibility depends on product, quantity, source availability, documentation requirements, and destination market.

Sample availability is reviewed product-wise. Factors include the API, source manufacturer, regulatory classification, sample quantity, required documentation, intended end-use, and destination country. Buyers should share complete details at the inquiry stage.

Yes. CLAYRAS welcomes repeat procurement, annual supply planning, continuity-focused API supply, and long-term export communication. Feasibility depends on API, volume, frequency, destination market, documentation requirements, and commercial terms.

Buyers should share API name, CAS number, required grade, target quantity, destination country, documentation requirements, and preferred shipment timeline. Complete requirements help CLAYRAS provide a faster and more accurate review.